Key result
Metabolic correction and HF therapy improve cardiac function in a neonate with ACTN2-related LVNC.
Why the study?
Neonatal cases of left ventricular non-compaction, particularly those presenting with severe metabolic disturbances, are uncommon.
A de novo ACTN2 deletion was identified in a neonate with LVNC and metabolic disturbances, expanding the phenotypic spectrum of ACTN2-related cardiomyopathies.
May support metabolic correction plus HF therapy in neonates with ACTN2-LVNC; extends phenotypic spectrum but remains hypothesis-generating.
Left ventricular non‐compaction (LVNC) is a rare cardiomyopathy characterized by prominent trabeculations and deep recesses. Neonatal cases, particularly with severe metabolic disturbances, are uncommon. We report a 2‐day‐old neonate with LVNC and dilated cardiomyopathy, presenting recurrent heart failure associated with hyperkalemia, metabolic acidosis, hyperlactatemia, and hypoglycemia. Management included mechanical ventilation, metabolic correction, and heart failure therapy, leading to improved cardiac function. Genetic analysis revealed a de novo heterozygous pathogenic ACTN2 deletion spanning exons 2–6. This case broadens the phenotypic spectrum of ACTN2 ‐related LVNC and suggests a potential link between metabolic disturbances and cardiac deterioration.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question. Management of a neonate with ACTN2-related left ventricular non-compaction and severe metabolic disturbances improved cardiac function after metabolic correction and heart failure therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: